News
-
-
PRESS RELEASE
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Protagonist Therapeutics presents new data on icotrokinra and PN-881 at SID Annual Meeting showcasing significant skin clearance and safety profile -
-
-
-
-
-
-
-
PRESS RELEASE
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Protagonist Therapeutics reports 84% of adolescents with moderate-to-severe plaque psoriasis achieved clear skin at Week 16 with icotrokinra in the ICONIC-LEAD Phase 3 study, showing potential as a first-line therapy
